Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
22:54
The Oil Terminal Union announces the initiation of the collective labor conflict on August 24, after the failure of negotiations for a salary increase of 6.5%.
22:34
Russia is recalling its ambassador from the United Kingdom amid diplomatic tensions
22:16
USA: The FDA has authorized the Aletta robot, the first robotic device that collects blood, under the supervision of a specialist.
21:50
The second fragment of the Gerbera drone, with explosive charge, discovered and neutralized on the Romanian coast
21:30
Volodymyr Zelensky stated that Ukraine was not involved in the sabotage of the Nord Stream pipeline.
See more news